News und Analysen
Pfizer Prices $31,000,000,000 Debt Offering
Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the pricing of a debt offering consisting of eight tranches of notes (collectively, the “Notes”):
$3,000,000,000 aggregate principal amount of
Pfizer Prices $31,000,000,000 Debt Offering
Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the pricing of a debt offering consisting of eight tranches of notes (collectively, the “Notes”):
$3,000,000,000 aggregate principal amount of
Agilent Wins SEAL Award for Innovative Products that Help Customers Achieve Their Sustainability Goals
Agilent Technologies Inc. (NYSE: A) today received a SEAL Business Sustainability Award for producing products and technology that are helping analytical and clinical labs reduce their carbon
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership
ICON releases its 2022 ICON Cares ESG Report
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. The
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Inogen to Present at 43rd Annual William Blair Growth Stock Conference
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in the William
Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a
Pfizer Announces Proposed Notes Offering
Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. (the “Issuer”), has commenced a multi-series offering of senior
Pfizer Announces Proposed Notes Offering
Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. (the “Issuer”), has commenced a multi-series offering of senior
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
Humana to Partner with Two National Durable Medical Equipment Organizations
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has reached agreement with two national organizations to provide Durable Medical Equipment (DME) services to
Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM
Transgene provides business update and Q1 2023 financial position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced data from the kidney biopsy sub-study of the AURORA clinical trial program (AURORA 1 and AURORA 2 Extension